VitalStone Financial’s NRX Pharmaceuticals NRXP Stock Holding History

VitalStone Financial’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1	Closed	–	–	1000
2023 Q1	$0	Buy	+1	New	+$10	﹤0.01%	458

Other funds holding NRXP

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VitalStone Financial's NRXP Position: Q2 2023 in Review

VitalStone Financial sold out of NRX Pharmaceuticals (NRXP) in Q2 2023, closing a stake of 1 share.

VitalStone Financial first reported a position in NRXP in Q1 2023 and held it in 1 quarter. The position peaked at $0 in Q1 2023. 32 funds tracked by Wall St. Rank hold NRXP as of Q2 2023.

VitalStone Financial reported no remaining NRX Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
VitalStone Financial sold 1 NRX Pharmaceuticals share in Q2 2023.
VitalStone Financial first reported a position in NRX Pharmaceuticals in Q1 2023 and held it in 1 quarter.
VitalStone Financial's NRX Pharmaceuticals position peaked at $0 in Q1 2023.
32 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2023.

Based on VitalStone Financial's 13F filing for Q2 2023, filed 21 Aug 2023.